[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Chung C, Kao MS, Gersell D: Incidental placental choriocarcinoma in a term pregnancy: a case report. J Med Case Rep; 2008;2:330

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental placental choriocarcinoma in a term pregnancy: a case report.
  • INTRODUCTION: Gestational choriocarcinoma occurs in 1 in 40,000 pregnancies.
  • Of all forms of gestational choriocarcinoma, placental choriocarcinoma is the most rare.
  • Maternal choriocarcinoma is usually diagnosed in symptomatic patients with metastases.
  • The incidental finding of a choriocarcinoma confined to the placenta with no evidence of dissemination to the mother, or infant is the least common scenario.
  • Her placenta revealed intraplacental choriocarcinoma.
  • No chemotherapy was initiated.
  • Metastasis was ruled out by chest x-ray and whole body computed tomography scan.
  • CONCLUSION: Due to the potential fatal outcome of placental choriocarcinoma, careful evaluation of both mother and infant after the diagnosis is made is important.
  • The incidence of placental choriocarcinoma may actually be higher than expected since it is not routine practice to send placentas for pathological evaluation after a normal spontaneous delivery.
  • The obstetrician, pathologist, and pediatrician should have an increased awareness of placental choriocarcinoma and its manifestations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Gynaecol Oncol. 1996;17(6):510-1 [8971530.001]
  • [Cites] Am J Surg Pathol. 1981 Apr;5(3):267-77 [7235120.001]
  • [Cites] Obstet Gynecol. 1990 Sep;76(3 Pt 2):494-7 [1696367.001]
  • [Cites] Asia Oceania J Obstet Gynaecol. 1994 Dec;20(4):367-73 [7832668.001]
  • (PMID = 18922186.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2577684
  •  go-up   go-down


2. Braun-Parvez L, Charlin E, Caillard S, Ducloux D, Wolf P, Rolle F, Golfier F, Flicoteaux H, Bergerat JP, Moulin B: Gestational choriocarcinoma transmission following multiorgan donation. Am J Transplant; 2010 Nov;10(11):2541-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gestational choriocarcinoma transmission following multiorgan donation.
  • An accidental transmission of placental choriocarcinoma (CC) from a multiorgan donor to four recipients is reported.
  • Histological examination demonstrated the presence of a placental CC.
  • Diagnosis of CC transmission was established on the basis of an increase of human chorionic gonadotrophin hormone (hCG) level.
  • The recipient of combined pancreas-kidney is still in complete remission 2 years after the beginning of chemotherapy without removal of the grafted organs which show optimal function.
  • Liver recipient showed intestinal metastasis and died from digestive hemorrhage after an initial response to chemotherapy.
  • Chemotherapy combined or not with transplantectomy in case of nonvital organ, should be discussed.
  • [MeSH-major] Choriocarcinoma / secondary. Kidney Transplantation / adverse effects. Liver Transplantation / adverse effects. Pancreas Transplantation / adverse effects. Uterine Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin / blood. Female. Humans. Immunosuppression / adverse effects. Male. Middle Aged. Pregnancy. Remission Induction. Tissue Donors

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 The Authors Journal compilation©2010 The American Society of Transplantation and the American Society of Transplant Surgeons.
  • (PMID = 20977645.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


3. Cavaliere A, Ermito S, Dinatale A, Pedata R: Management of molar pregnancy. J Prenat Med; 2009 Jan;3(1):15-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gestational Trophoblastic Disease (GTD) originates from placental tissue and is among the rare human tumors that can be cured even in the presence of widespread metastases.
  • GTD include a spectrum of interrelated tumors including complete and partial hydatidiform mole, invasive mole, choriocarcinoma, and placental site trophoblastic tumor, that have different propensities for local invasion and spread.
  • Although most GTD develop after a mole, they can follow any antecedent pregnancy.Transvaginal ultrasound, routinary dosage of beta-hCG and current approaches to chemotherapy, let most women with malignant gestational trophoblastic disease to be cured and their reproductive function preserved.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22439034.001).
  • [ISSN] 1971-3282
  • [Journal-full-title] Journal of prenatal medicine
  • [ISO-abbreviation] J Prenat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3279094
  • [Keywords] NOTNLM ; chemotherapy / gestational trophoblastic disease / human chorionic gonadotropin
  •  go-up   go-down


Advertisement
4. Kendall A, Gillmore R, Newlands E: Chemotherapy for trophoblastic disease: current standards. Curr Opin Obstet Gynecol; 2002 Feb;14(1):33-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for trophoblastic disease: current standards.
  • Gestational trophoblastic diseases comprise a rare spectrum of disorders in which the normal regulatory mechanisms controlling the behaviour of trophoblastic tissue are lost.
  • They vary from the benign complete and partial hydatidiform moles to the frankly malignant choriocarcinoma and placental site trophoblastic tumours.
  • The majority will be cured by suction curettage, followed by human chorionic gonadotrophin screening, but some will go on to need chemotherapy.
  • Patients should have their treatment stratified according to various prognostic factors in order to ensure firstly their disease is eliminated and secondly to reduce the incidence of long-term treatment complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Trophoblastic Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Leucovorin / administration & dosage. Methotrexate / administration & dosage. Neoplasm Staging. Pregnancy. Prognosis. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11801874.001).
  • [ISSN] 1040-872X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 13
  •  go-up   go-down


5. Topuz S, Iyibozkurt C, Mete O, Akhan S, Salihoğlu Y, Bengisu E, Berkman S: Life-saving hysterectomy in choriocarcinoma: presentation of two cases. Eur J Gynaecol Oncol; 2008;29(6):664-5
MedlinePlus Health Information. consumer health - Vaginal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Life-saving hysterectomy in choriocarcinoma: presentation of two cases.
  • BACKGROUND: Choriocarcinoma is a malignant tumor of the placenta.
  • Life-saving hysterectomy was performed in two cases with choriocarcinoma who had profuse vaginal bleeding.
  • CASE 1: A 25-year-old, gravida 3, para 1, woman was referred to our emergency clinic with the diagnosis of choriocarcinoma and massive vaginal bleeding.
  • CASE 2: A 54-year-old, gravida 3, para 3, woman was referred to our clinic with heavy bleeding with the diagnosis of choriocarcinoma.
  • Chemotherapy was planned but as sudden vaginal bleeding began she was referred to the Gynecology Department.
  • CONCLUSION: Although chemotherapy is the cornerstone of treatment for choriocarcinoma, optimal treatment results may depend on the addition of surgery in selected circumstances.
  • [MeSH-major] Choriocarcinoma / surgery. Hysterectomy. Uterine Hemorrhage / surgery. Uterine Neoplasms / surgery

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115703.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Zhao J, Xiang Y, Wan XR, Feng FZ, Cui QC, Yang XY: Molecular genetic analyses of choriocarcinoma. Placenta; 2009 Sep;30(9):816-20
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic analyses of choriocarcinoma.
  • BACKGROUND: Choriocarcinoma is a highly malignant trophoblastic neoplasm.
  • The genetic origin, immunogenicity, sensitivity to chemotherapy and prognosis of these two kinds of conditions are quite different, so identification of these two kinds of choriocarcinoma is of great importance.
  • The objective of this study is to distinguish choriocarcinoma as gestational or non-gestational and identify the causative pregnancy of gestational choriocarcinoma through molecular genetic analysis.
  • METHODS: Twelve patients with choriocarcinoma, who had experienced surgery prior to chemotherapy, were enrolled in this study.
  • In order to prepare DNA from choriocarcinoma tissue, areas of choriocarcinoma were firstly microdissected from haematoxylin and eosin-stained sections.
  • PCR amplification and fluorescent microsatellite genotyping were performed using DNA from the couples and captured tissue.
  • The genetic contributions to the choriocarcinoma were determined by comparing the genotypes of the choriocarcinoma and that of the couples.
  • CONCLUSION: Microsatellite polymorphism analysis is a molecular approach for distinguishing the non-gestational choriocarcinoma from the gestational one, and can also be used to identify the causative pregnancy of gestational choriocarcinoma.
  • Antecedent pregnancy prior to choriocarcinoma is not always its causative pregnancy.
  • [MeSH-major] Choriocarcinoma, Non-gestational / genetics. Gestational Trophoblastic Disease / genetics. Hydatidiform Mole / genetics. Uterine Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Alleles. DNA / blood. Diagnosis, Differential. Female. Genotype. Humans. Microsatellite Instability. Pregnancy. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647314.001).
  • [ISSN] 1532-3102
  • [Journal-full-title] Placenta
  • [ISO-abbreviation] Placenta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9007-49-2 / DNA
  •  go-up   go-down


7. Liu J, Guo L: Intraplacental choriocarcinoma in a term placenta with both maternal and infantile metastases: a case report and review of the literature. Gynecol Oncol; 2006 Dec;103(3):1147-51
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraplacental choriocarcinoma in a term placenta with both maternal and infantile metastases: a case report and review of the literature.
  • BACKGROUND: Intraplacental choriocarcinoma is rare, and usually results in maternal metastasis at the time of diagnosis.
  • Intraplacental choriocarcinoma involves both mother and infant is extremely rare.
  • There was only one case report of intraplacental choriocarcinoma with confirmed metastases involving both the mother and the infant.
  • CASE: We describe a second case of intraplacental choriocarcinoma in a term placenta with both maternal and infantile metastases.
  • Grossly, the primary lesion of the placenta resembled an old infarct.
  • Both the mother and the infant received chemotherapy and were alive without disease after one year's follow-up.
  • CONCLUSION: The optimal treatment for intraplacental choriocarcinoma is controversial.
  • However, aggressive chemotherapy is suggested for patients with metastatic disease.
  • [MeSH-major] Choriocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Placenta Diseases / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Female. Humans. Infant, Newborn. Male. Neoplasm Metastasis. Pregnancy

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17005243.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


8. Kendall A, Gillmore R, Newlands E: Chemotherapy for trophoblastic disease: current standards. Expert Rev Anticancer Ther; 2003 Feb;3(1):48-54
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for trophoblastic disease: current standards.
  • Gestational trophoblastic diseases comprise a rare spectrum of disorders in which the normal regulatory mechanisms controlling the behavior of trophoblastic tissue are lost.
  • They vary from the benign complete and partial hydatidiform moles to the frankly malignant choriocarcinoma and placental site trophoblastic tumors.
  • The majority will be cured by suction curettage, followed by human chorionic gonadotrphin screening but some will go on to need chemotherapy.
  • Patients should have their treatment stratified according to various prognostic factors in order to ensure firstly their disease is eliminated and secondly to reduce the incidence of long-term treatment complications.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Trophoblastic Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Drug Resistance, Neoplasm. Female. Humans. Neoplasm Staging. Placenta / pathology. Pregnancy. Prognosis. Risk Assessment

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12597349.001).
  • [ISSN] 1473-7140
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 14
  •  go-up   go-down


9. Landau D, Maor E, Maymon E, Rabinovich A, Piura B: Intraplacental choriocarcinoma metastasizing to the maternal lung. Eur J Gynaecol Oncol; 2006;27(1):29-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraplacental choriocarcinoma metastasizing to the maternal lung.
  • BACKGROUND: Although normal pregnancy is the precursor of 25% of cases of maternal choriocarcinoma, intraplacental choriocarcinoma in an otherwise normal placenta associated with viable pregnancy has rarely been reported.
  • CASE: Examination of the placenta after delivery of a pale and small-for-date infant at term revealed intraplacental choriocarcinoma.
  • The mother refused chemotherapy and disappeared from follow-up.
  • Nine months later, she presented with metastatic choriocarcinoma of the lung.
  • Eleven courses of the multi-drug EMA CO regimen effected a decrease of beta-HCG to normal and disappearance of lung metastases.
  • To date, 28 months after the end of chemotherapy, the patient is alive and without evidence of gestational trophoblastic disease.
  • CONCLUSIONS: This case is an example of natural disease progression of intraplacental choriocarcinoma metastasizing to the mother.
  • Furthermore, it supports common knowledge that the multi-drug EMA CO regimen is effective treatment in poor prognosis metastatic choriocarcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Choriocarcinoma / secondary. Lung Neoplasms / secondary. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Outcome. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Female. Follow-Up Studies. Gestational Age. Humans. Immunohistochemistry. Neoplasm Staging. Placenta / pathology. Pregnancy. Radiography, Thoracic. Risk Assessment. Treatment Outcome. Treatment Refusal


10. Blohm ME, Göbel U: Unexplained anaemia and failure to thrive as initial symptoms of infantile choriocarcinoma: a review. Eur J Pediatr; 2004 Jan;163(1):1-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexplained anaemia and failure to thrive as initial symptoms of infantile choriocarcinoma: a review.
  • Infantile choriocarcinoma is a highly malignant germ cell tumour sub-entity thought to originate from the placenta.
  • The aim of this review is to alert clinicians to clinical symptoms and course of neonatal/infantile choriocarcinoma in order to improve the prognosis of affected children by early diagnosis and appropriate treatment.
  • Children suffering from infantile choriocarcinoma become symptomatic at a median age of 1 month (range 0 days-5 months).
  • Without appropriate anti-neoplastic treatment, infantile death occurs on average within 3 weeks from first presentation with a high rate of post-mortem diagnoses (9/28, 32% of live born infants).
  • In recent years, five reported patients (5/30, 18%) achieved a sustained remission after multi-agent cisplatinum-based chemotherapy and delayed (4/5) or primary tumour resection (1/5).
  • Maternal choriocarcinoma was reported in 17 of the 30 cases.
  • CONCLUSION: The differential diagnosis of infantile anaemia, failure to thrive and liver enlargement should include infantile choriocarcinoma and prompt measurement of beta-human chorionic gonadotropin.
  • [MeSH-major] Anemia / etiology. Choriocarcinoma / diagnosis. Failure to Thrive / etiology. Hepatomegaly / etiology. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Infant. Infant, Newborn. Male. Placenta Diseases. Pregnancy. Treatment Outcome

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1995 Dec;25(6):475-8 [7565312.001]
  • [Cites] Gynecol Oncol. 1986 May;24(1):113-9 [3699573.001]
  • [Cites] Pediatr Radiol. 1993;23(2):79-82 [8516048.001]
  • [Cites] Med Pediatr Oncol. 2002 Mar;38(3):203-4 [11836724.001]
  • [Cites] Med Pediatr Oncol. 2001 Apr;36(4):497-9 [11260576.001]
  • [Cites] Wien Klin Wochenschr. 2003 Jan 31;115(1-2):29-35 [12658908.001]
  • [Cites] Am J Clin Pathol. 1977 Mar;67(3):279-83 [320862.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Jan-Feb;18(1):11-26 [11205836.001]
  • [Cites] J Neurosurg. 1971 Oct;35(4):465-71 [5167345.001]
  • [Cites] Med Pediatr Oncol. 2002 Mar;38(3):187-91; discussion 192 [11836719.001]
  • [Cites] J Pediatr Surg. 1992 Oct;27(10):1318-9 [1383486.001]
  • [Cites] Br J Obstet Gynaecol. 1989 Feb;96(2):241-4 [2649145.001]
  • [Cites] J Pathol Bacteriol. 1952 Oct;64(4):735-9 [13000587.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(1):72-8 [11165132.001]
  • [Cites] Pediatr Pathol. 1993 Nov-Dec;13(6):723-30 [8108292.001]
  • [Cites] J Am Acad Dermatol. 1986 May;14(5 Pt 2):918-27 [3711401.001]
  • [Cites] J Am Med Assoc. 1958 Feb 1;166(5):482-3 [13491359.001]
  • [Cites] Arch Pathol Lab Med. 1990 Oct;114(10):1079-82 [2222151.001]
  • [Cites] Acta Oncol. 1992;31(1):99-106 [1586509.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):2028-32 [8364882.001]
  • [Cites] Acta Paediatr Jpn. 1992 Feb;34(1):52-9 [1580153.001]
  • [Cites] Am J Perinatol. 1997 Feb;14 (2):79-82 [9259903.001]
  • [Cites] Br J Obstet Gynaecol. 1995 Sep;102(9):715-9 [7547762.001]
  • [Cites] Am J Pathol. 1953 May-Jun;29(3):555-67 [13040493.001]
  • [Cites] Pediatr Radiol. 1996 Dec;26(12 ):869-70 [8929298.001]
  • [Cites] J Pediatr Surg. 2000 Jul;35(7):1134-5 [10917316.001]
  • [Cites] J Obstet Gynaecol Br Emp. 1961 Feb;68:144-9 [13719245.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1993 May;15(2):268-9 [8498651.001]
  • [Cites] J Pediatr. 1968 Sep;73(3):374-8 [5667419.001]
  • [Cites] J Gynecol Obstet Biol Reprod (Paris). 1993;22(7):789-92 [8308208.001]
  • [Cites] Acta Pathol Jpn. 1981 Mar;31(2):317-22 [7257771.001]
  • [Cites] Arch Fr Pediatr. 1981 May;38(5):351-2 [7259421.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):1033-7 [12213732.001]
  • [Cites] J Obstet Gynaecol Res. 1996 Dec;22(6):585-8 [9037948.001]
  • [Cites] J Obstet Gynaecol Br Emp. 1954 Jun;61(3):329-30 [13175059.001]
  • (PMID = 14628141.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  • [Number-of-references] 36
  •  go-up   go-down


11. Lurain JR: Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol; 2010 Dec;203(6):531-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole.
  • Gestational trophoblastic disease includes hydatidiform mole (complete and partial) and gestational trophoblastic neoplasia (invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor).
  • The epidemiology, pathology, clinical presentation, and diagnosis of each of these trophoblastic disease variants are discussed.
  • Particular emphasis is given to management of hydatidiform mole, including evacuation, twin mole/normal fetus pregnancy, prophylactic chemotherapy, and follow-up.
  • [MeSH-major] Gestational Trophoblastic Disease / drug therapy. Gestational Trophoblastic Disease / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Abortion, Therapeutic / methods. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choriocarcinoma / diagnosis. Choriocarcinoma / drug therapy. Choriocarcinoma / mortality. Choriocarcinoma / pathology. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hydatidiform Mole / drug therapy. Hydatidiform Mole / pathology. Hysterectomy / methods. Pregnancy. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20728069.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


12. Noh HT, Lee KH, Lee MA, Ko YB, Hwang SH, Son SK: Epithelioid trophoblastic tumor of paracervix and parametrium. Int J Gynecol Cancer; 2008 Jul-Aug;18(4):843-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelioid trophoblastic tumor (ETT) is an unusual variant of gestational trophoblastic tumor that is closely related to choriocarcinoma and placental site trophoblastic tumor but shows different morphologic and immunohistochemical features.
  • We report an ETT discovered in paracervix, parametrium, and periadnexal soft tissue of a 44-year-old woman.
  • She underwent laparoscopic surgery and four courses of chemotherapy with a regimen of etoposide, methotrexate, and dactinomycin.
  • [MeSH-major] Carcinoma / diagnosis. Pelvic Neoplasms / diagnosis. Trophoblastic Neoplasms / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cervix Uteri / pathology. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17944924.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Morgan JM, Lurain JR: Gestational trophoblastic neoplasia: an update. Curr Oncol Rep; 2008 Nov;10(6):497-504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gestational trophoblastic neoplasia (GTN) includes invasive mole, choriocarcinoma, and placental site trophoblastic tumors.
  • Thorough evaluation and staging allow selection of appropriate therapy that maximizes chances for cure while minimizing toxicity.
  • Nonmetastatic (stage I) and low-risk metastatic (stages II and III, World Health Organization score < 7) GTN can be treated with single-agent chemotherapy, resulting in a survival rate approaching 100%.
  • High-risk metastatic GTN (stage IV, WHO score > or = 7) requires initial multiagent chemotherapy with or without adjuvant radiation and surgery to achieve a survival rate of 80% to 90%.
  • [MeSH-major] Gestational Trophoblastic Disease / drug therapy. Trophoblastic Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Chorionic Gonadotropin / metabolism. Drug Design. Female. Follow-Up Studies. Humans. Medical Oncology / methods. Neoplasm Metastasis. Pregnancy. Pregnancy Complications, Neoplastic. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1996 Jun;174(6):1917-23; discussion 1923-4 [8678159.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):156-9 [8995566.001]
  • [Cites] J Reprod Med. 2006 Oct;51(10):829-34 [17086812.001]
  • [Cites] Am J Obstet Gynecol. 2000 Dec;183(6):1579-82 [11120531.001]
  • [Cites] Gynecol Oncol. 2006 Mar;100(3):511-20 [16246400.001]
  • [Cites] Br J Obstet Gynaecol. 1989 Jul;96(7):795-802 [2548568.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18(2):357-62 [17711444.001]
  • [Cites] Gynecol Oncol. 1996 Feb;60(2):292-4 [8631554.001]
  • [Cites] Obstet Gynecol. 1988 Sep;72(3 Pt 1):413-8 [2457192.001]
  • [Cites] Br J Obstet Gynaecol. 1991 Jun;98(6):550-7 [1651757.001]
  • [Cites] Obstet Gynecol. 1985 Jun;65(6):830-6 [2987766.001]
  • [Cites] J Reprod Med. 1991 Jan;36(1):36-9 [1848898.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):603-7 [16085293.001]
  • [Cites] Gynecol Oncol. 1998 Nov;71(2):247-53 [9826467.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1432-8 [16803542.001]
  • [Cites] Am J Obstet Gynecol. 2007 Feb;196(2):95-6 [17306644.001]
  • [Cites] Obstet Gynecol. 2006 Jul;108(1):176-87 [16816073.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):552-7 [14675675.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):732-7 [17299394.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):587-90 [16750258.001]
  • [Cites] Int J Gynaecol Obstet. 2007 Jul;98 (1):44-7 [17481633.001]
  • [Cites] Semin Oncol. 1982 Jun;9(2):198-203 [7123267.001]
  • [Cites] Gynecol Oncol. 1980 Feb;9(1):18-22 [6243597.001]
  • [Cites] Gynecol Oncol. 1990 Jan;36(1):56-9 [2153091.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):486-91 [17762576.001]
  • [Cites] Am J Obstet Gynecol. 1995 Feb;172(2 Pt 1):574-9 [7856688.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2636-43 [9215835.001]
  • [Cites] Gynecol Oncol. 1986 Jan;23(1):111-8 [3002916.001]
  • [Cites] J Reprod Med. 2002 May;47(5):355-62 [12063874.001]
  • [Cites] J Reprod Med. 2002 Jun;47(6):460-4 [12092014.001]
  • [Cites] Obstet Gynecol. 1989 Mar;73(3 Pt 1):357-62 [2536911.001]
  • [Cites] J Reprod Med. 2006 Oct;51(10):767-72 [17086804.001]
  • [Cites] Obstet Gynecol. 2008 Aug;112(2 Pt 1):251-8 [18669719.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:175-7 [14763174.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):151-9 [16631241.001]
  • [Cites] Am J Obstet Gynecol. 1985 May 1;152(1):59-62 [2986458.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):149-53 [17931696.001]
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1393-403 [9808132.001]
  • [Cites] Radiology. 1996 Jul;200(1):277-80 [8657926.001]
  • [Cites] Expert Opin Pharmacother. 2003 Nov;4(11):2005-17 [14596654.001]
  • [Cites] Curr Treat Options Oncol. 2002 Apr;3(2):113-24 [12057074.001]
  • [Cites] J Reprod Med. 2008 Jul;53(7):535-40 [18720930.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1578-83 [18453518.001]
  • [Cites] J Reprod Med. 2006 Oct;51(10):773-6 [17086805.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):618-23 [15863169.001]
  • [Cites] Gynecol Oncol. 2000 Jul;78(1):28-31 [10873405.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):282-7 [7522198.001]
  • [Cites] Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1124-30 [17386047.001]
  • [Cites] Gynecol Oncol. 1994 Jul;54(1):76-9 [8020843.001]
  • (PMID = 18928664.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin
  • [Number-of-references] 51
  •  go-up   go-down


14. Zhou Q, Lei XY, Xie Q, Cardoza JD: Sonographic and Doppler imaging in the diagnosis and treatment of gestational trophoblastic disease: a 12-year experience. J Ultrasound Med; 2005 Jan;24(1):15-24
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic and Doppler imaging in the diagnosis and treatment of gestational trophoblastic disease: a 12-year experience.
  • OBJECTIVE: To evaluate the clinical utility of sonography with Doppler examination in the diagnosis and treatment of gestational trophoblastic disease (GTD).
  • Sonographic and Doppler examinations were performed to diagnose the presence of molar tissue, detect invasive disease, assess disease recurrence, and monitor the efficacy of chemotherapy.
  • RESULTS: Of the 355 patients with GTD, 106 had a classic hydatidiform mole (CHM), 33 had a partial hydatidiform mole (PHM), 184 had an invasive hydatidiform mole (IHM), and 32 had choriocarcinoma.
  • Sonography showed abnormal molar tissue confined to the endometrial cavity in all cases of CHM.
  • In cases of IHM and choriocarcinoma, soft tissue invasion and cystic vascular spaces within the myometrium were shown.
  • Cases of PHM had a thickened, hydropic placenta with a concomitant fetus.
  • Doppler waveforms showed resistive indices of 0.55 (SD, 0.06) for CHM, 0.56 (SD, 0.04) for PHM, 0.28 (SD, 0.06) for IHM, 0.25 (SD, 0.05) for choriocarcinoma, and 0.66 (SD, 0.04) for normal pregnancies.
  • The abnormal sonographic and Doppler findings in invasive disease resolved when chemotherapy was successful.
  • CONCLUSIONS: Sonography and Doppler imaging were helpful in diagnosing GTD, in determining whether invasive disease was present, in detecting recurrence of disease, and in following the effectiveness of chemotherapy.
  • [MeSH-minor] Adult. Choriocarcinoma / ultrasonography. Female. Humans. Hydatidiform Mole / ultrasonography. Middle Aged. Pregnancy. Ultrasonography, Doppler

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15615924.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Feng FZ, Xiang Y, Wan XR, Yin SJ, Yang XY: [Clinical characteristics and management of gestational trophoblastic disease in women aged 50 years or more]. Zhonghua Fu Chan Ke Za Zhi; 2005 Sep;40(9):605-8
Genetic Alliance. consumer health - Gestational Trophoblastic Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesions included 5 hydatidiform moles (13%), 19 invasive moles (50%), 12 choriocarcinomas (32%) and 2 placenta site trophoblastic tumors (5%).
  • Twenty-three cases of hydatidiform moles were diagnosed at their first visit to the hospital, and 15 of them received prophylactic chemotherapy, of whom 10 progressed to invasive mole, 3 developed lung metastasis.
  • All of the other 8 cases without prophylactic chemotherapy progressed to malignant changes with metastasis of lung.
  • The use of prophylactic chemotherapy reduced the incidence of subsequent metastasis.
  • All of 38 cases received chemotherapy.
  • CONCLUSIONS: The diagnosis of pregnancy and pregnancy-related disease should be considered in the elderly women presenting with abnormal vaginal bleeding.
  • Once gestational trophoblastic disease in women aged 50 years or more is diagnosed, chemotherapy should be given as soon as possible.
  • [MeSH-major] Gestational Trophoblastic Disease / diagnosis. Gestational Trophoblastic Disease / drug therapy
  • [MeSH-minor] Choriocarcinoma / diagnosis. Choriocarcinoma / drug therapy. Choriocarcinoma / surgery. Female. Humans. Hydatidiform Mole / diagnosis. Hydatidiform Mole / drug therapy. Hydatidiform Mole / surgery. Middle Aged. Pregnancy. Prognosis. Retrospective Studies. Time Factors. Treatment Outcome. Uterine Hemorrhage / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202316.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Cole LA, Khanlian SA: Inappropriate management of women with persistent low hCG results. J Reprod Med; 2004 Jun;49(6):423-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Quiescent gestational trophoblastic disease (GTD) was identified in 121 cases by the absence of invasive trophoblast antigen and nonresponse to chemotherapy (64 cases with a history of hydatidiform mole or gestational trophoblastic neoplasia (GTN) and 57 cases following antecedent pregnancy).
  • Another 61 Reference Service cases hadfalse positive hCG, and we observed 7 cases with low levels of hCG of pituitary origin (hCG subsequently suppressed by estrogen-progesterone medication).
  • Most disturbing is that the majority of these cases (68%) received needless therapy for assumed GTN/choriocarcinoma/placental site trophoblastic tumor before consultation with the Reference Service.
  • One hundred twenty-eight of the 189 patients (77 of 121 with quiescent GTD, 48 of 61 withfalse positive hCG and 3 of 7 with pituitary hCG) underwent therapy ranging from single-agent chemotherapy (117 cases), to EMA-CO combination chemotherapy (etoposide, methotrexate, actinomycin D alternating with cyclophosphamide and vincristine) (16 cases), to hysterectomy and/or bilateral salpingo-oophorectomy (31 cases).
  • False positive hCG and pituitary hCG would obviously not respond to these treatments, and no treated cases of quiescent GTD responded to chemotherapy orfully responded to hysterectomy.
  • The continued needless treatment of patients with quiescent GTD, even after multiple publications, is entirely avoidable.
  • [MeSH-major] Chorionic Gonadotropin / analysis. Diagnostic Errors. Gestational Trophoblastic Disease / diagnosis. Gestational Trophoblastic Disease / surgery. Hydatidiform Mole / diagnosis. Hydatidiform Mole / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. False Positive Reactions. Female. Humans. Hysterectomy. Ovariectomy. Pregnancy. Reference Values. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15283048.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD35654
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


17. Kohorn EI, Kacinski BM, Stanley ER: Serum levels of macrophage colony-stimulating factor in trophoblastic disease. Gynecol Oncol; 2001 Mar;80(3):383-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The aims of this study were to measure levels of colony stimulating factor (CSF-1) in patients with trophoblastic disease, to determine whether such measurement may be useful to supplement measurement of the prognostically reliable human chorionic gonadotrophin (hCG), and to assess whether measurement of CSF-1 may be helpful in predicting requirement for chemotherapy in patients with hydatidiform mole.
  • METHODS: Serial weekly serum samples were selected for CSF-1 assay from representative diagnostic groups of patients with trophoblastic disease: hydatidiform-mole with spontaneous resolution, low-risk post-hydatidiform-mole trophoblastic tumor, partial hydatidiform mole, high-risk metastatic gestational trophoblastic tumor, primary ovarian choriocarcinoma, and placental site trophoblastic tumor. hCG was measured by an in-house radioimmunoassay that measures all parts of the hCG molecule.
  • [MeSH-minor] Adolescent. Adult. Aged. Chorionic Gonadotropin / blood. Female. Humans. Hydatidiform Mole / blood. Hydatidiform Mole / drug therapy. Male. Middle Aged. Predictive Value of Tests. Pregnancy. Radioimmunoassay. Risk Factors

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11263936.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA26504; United States / NCI NIH HHS / CA / CA32551; United States / PHS HHS / / P30-13330
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


18. Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C: Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol; 2003 Nov;4(11):670-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gestational trophoblastic diseases (GTD) consist of a group of neoplastic disorders arising from placental trophoblastic tissue after normal or abnormal fertilisation.
  • The WHO classification of GTD includes hydatidiform mole, invasive mole, choriocarcinoma, placental site trophoblastic tumour, and miscellaneous and unclassified trophoblastic lesions.
  • GTD have a varying potential for local invasion and metastases and they generally respond to chemotherapy.
  • Maternal age and a history of GTD have been established as strong risk factors for hydatidiform mole and choriocarcinoma.
  • We review published data on the worldwide distribution of GTD, original data from cancer- registry-based statistics on choriocarcinoma, and major aetiological hypotheses, including parental age, AB0 blood groups, history of GTD, reproductive factors, oral contraceptive use, and other environmental factors.
  • [MeSH-minor] Choriocarcinoma / epidemiology. Humans. Incidence. Registries. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14602247.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 73
  •  go-up   go-down


19. Sasaki S: Management of gestational trophoblastic diseases in Japan--a review. Placenta; 2003 Apr;24 Suppl A:S28-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our hCG regression curve post-evacuation is quite useful for the detection of persistent trophoblastic diseases.
  • (2) invasive mole or metastatic moles; and (3) choriocarcinoma.
  • Post-molar persistent hCG presents no focus or histological findings except persistent elevated hCG, although single agent chemotherapy is required.
  • For the selection of the most appropriate chemotherapy, what we call a 'Diagnostic Score' is applied to differentiate choriocarcinoma from invasive moles or metastatic moles clinically in patients falling into these two groups.
  • This unique 'Diagnostic Score' for the detection of choriocarcinoma plays an important role in initial management in our protocol.
  • [MeSH-major] Gestational Trophoblastic Disease / therapy
  • [MeSH-minor] Algorithms. Antineoplastic Agents / therapeutic use. Choriocarcinoma / diagnosis. Choriocarcinoma / therapy. Chorionic Gonadotropin / blood. Combined Modality Therapy. Female. Humans. Hydatidiform Mole / diagnosis. Hydatidiform Mole / therapy. Hydatidiform Mole, Invasive / diagnosis. Hydatidiform Mole, Invasive / therapy. Japan. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12842411.001).
  • [ISSN] 0143-4004
  • [Journal-full-title] Placenta
  • [ISO-abbreviation] Placenta
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin
  • [Number-of-references] 6
  •  go-up   go-down


20. Nizam K, Haider G, Memon N, Haider A: Gestational trophoblastic disease: experience at Nawabshah Hospital. J Ayub Med Coll Abbottabad; 2009 Jan-Mar;21(1):94-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Gestational Trophoblastic Disease (GTD) is a heterogeneous group of diseases that includes partial and complete hydatidiform mole, invasive mole, choriocarcinoma and placental site trophoblastic tumour.
  • METHODS: The case records of all the gestational trophoblastic cases during study period were analysed regarding their history, clinical examination, investigations, treatment and follow-up.
  • The main outcomes were measured in terms of duration, antecedent pregnancy, investigations, treatment and the follow-up.
  • Of these 30 cases, 21 (70%) patients had hydatidiform mole, 7 (23.3%) patients had invasive disease and 2 (6.6%) patients had choriocarcinoma.
  • Twenty three patients (76.6%) received chemotherapy while 25 (83.3%) patients had suction evacuation and 4 (13.3%) patients underwent hysterectomy.
  • Hydatidiform mole was the commonest type of trophoblastic disease in these patients.
  • [MeSH-major] Gestational Trophoblastic Disease / diagnosis
  • [MeSH-minor] Adolescent. Adult. Choriocarcinoma / diagnosis. Choriocarcinoma / epidemiology. Choriocarcinoma / therapy. Chorionic Gonadotropin, beta Subunit, Human / blood. Female. Humans. Hydatidiform Mole / diagnosis. Hydatidiform Mole / epidemiology. Hydatidiform Mole / therapy. Hydatidiform Mole, Invasive / diagnosis. Hydatidiform Mole, Invasive / epidemiology. Hydatidiform Mole, Invasive / therapy. Incidence. Pakistan / epidemiology. Pregnancy. Retrospective Studies. Trophoblastic Tumor, Placental Site / diagnosis. Trophoblastic Tumor, Placental Site / epidemiology. Trophoblastic Tumor, Placental Site / therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / epidemiology. Uterine Neoplasms / therapy. Young Adult

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20364752.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


21. Lurain JR: Treatment of gestational trophoblastic tumors. Curr Treat Options Oncol; 2002 Apr;3(2):113-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of gestational trophoblastic tumors.
  • Gestational trophoblastic tumors (invasive mole, choriocarcinoma, and placental site trophoblastic tumor) should be classified according to the National Cancer Institute (NCI), World Health Organization (WHO), and International Federation of Gynecology and Obstetrics (FIGO) criteria into nonmetastatic, low-risk metastatic, and high-risk metastatic categories.
  • Metastatic high-risk tumors (FIGO Stage IV, WHO score > 7) require combination chemotherapy with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine (EMA-CO) with or without adjuvant radiation therapy and surgery to achieve cure rates of 80% to 90%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Trophoblastic Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Methotrexate / administration & dosage. Neoplasm Staging. Practice Guidelines as Topic. Pregnancy. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1996 Jun;174(6):1917-23; discussion 1923-4 [8678159.001]
  • [Cites] Obstet Gynecol. 1994 Dec;84(6):969-73 [7970479.001]
  • [Cites] J Reprod Med. 1998 Jan;43(1):44-52 [9475149.001]
  • [Cites] Cancer. 1990 Sep 1;66(5):978-82 [2167150.001]
  • [Cites] Am J Obstet Gynecol. 2000 Dec;183(6):1579-82 [11120531.001]
  • [Cites] Gynecol Oncol. 1984 Sep;19(1):53-6 [6088370.001]
  • [Cites] Br J Obstet Gynaecol. 1989 Jul;96(7):795-802 [2548568.001]
  • [Cites] Gynecol Oncol. 1996 Feb;60(2):292-4 [8631554.001]
  • [Cites] Obstet Gynecol. 1988 Sep;72(3 Pt 1):413-8 [2457192.001]
  • [Cites] Gynecol Oncol. 1983 Oct;16(2):190-5 [6313493.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(6):461-5 [7514124.001]
  • [Cites] Cancer. 1975 Sep;36(3):863-6 [171055.001]
  • [Cites] J Vasc Interv Radiol. 1991 Nov;2(4):517-22 [1797218.001]
  • [Cites] Cancer. 1980 Dec 15;46(12):2723-30 [7192596.001]
  • [Cites] J Reprod Med. 1991 Jan;36(1):36-9 [1848898.001]
  • [Cites] Gynecol Oncol. 1998 Nov;71(2):247-53 [9826467.001]
  • [Cites] Am J Obstet Gynecol. 1982 Sep 1;144(1):88-92 [6287843.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2173-6 [2449942.001]
  • [Cites] Am J Obstet Gynecol. 1991 Feb;164(2):611-6 [1847005.001]
  • [Cites] Gynecol Oncol. 1980 Feb;9(1):18-22 [6243597.001]
  • [Cites] Gynecol Oncol. 1990 Jan;36(1):56-9 [2153091.001]
  • [Cites] Am J Obstet Gynecol. 1995 Feb;172(2 Pt 1):574-9 [7856688.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2636-43 [9215835.001]
  • [Cites] Gynecol Oncol. 1986 Jan;23(1):111-8 [3002916.001]
  • [Cites] J Clin Oncol. 1989 Jul;7(7):900-3 [2472471.001]
  • [Cites] J Surg Oncol. 1989 Jul;41(3):148-52 [2545973.001]
  • [Cites] Am J Obstet Gynecol. 1973 Feb 15;115(4):451-7 [4346614.001]
  • [Cites] Am J Obstet Gynecol. 1985 May 1;152(1):59-62 [2986458.001]
  • [Cites] Radiology. 1996 Jul;200(1):277-80 [8657926.001]
  • [Cites] Gynecol Oncol. 2000 Jul;78(1):28-31 [10873405.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):282-7 [7522198.001]
  • [Cites] J Reprod Med. 1998 Jan;43(1):53-9 [9475150.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):854-9 [10673528.001]
  • [Cites] Gynecol Oncol. 1994 Jul;54(1):76-9 [8020843.001]
  • (PMID = 12057074.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 40
  •  go-up   go-down


22. Horn LC, Vogel M: [Gestational trophoblastic disease. Non-villous forms of gestational trophoblastic disease]. Pathologe; 2004 Jul;25(4):281-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The non-villous forms of gestational trophoblastic disease (GTD) include a wide range of morphologic different lesions and cover a wide range of differential diagnosis.
  • An early start of chemotherapy is of great prognostic impact.
  • Placental site nodule (PSN) and exaggerated placental site (EPS) are non-neoplastic lesions of the intermediate trophoblast without tumorous appearance, whereas placental site trophoblastic tumor (PSTT) and epitheloid trophoblastic tumor (ETT) represent tumorous neoplasms with a potential for local invasion and metastases.
  • [MeSH-major] Choriocarcinoma / pathology. Pregnancy Complications / pathology. Trophoblasts / pathology
  • [MeSH-minor] Female. Gestational Trophoblastic Disease / pathology. Humans. Placenta / pathology. Pregnancy. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1999 May;73(2):216-22 [10329037.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1994 Jun;54(6):375-7 [8088495.001]
  • [Cites] Am J Surg Pathol. 1990 Nov;14(11):1001-9 [2240354.001]
  • [Cites] Gen Diagn Pathol. 1997 Nov;143(2-3):159-71 [9443572.001]
  • [Cites] Hum Pathol. 1999 Jun;30(6):687-94 [10374778.001]
  • [Cites] Zentralbl Gynakol. 1996;118(11):591-7 [9082691.001]
  • [Cites] Gynecol Oncol. 1999 Aug;74(2):302-3 [10419751.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1558-62 [11075860.001]
  • [Cites] Gen Diagn Pathol. 1997 Nov;143(2-3):191-6 [9443576.001]
  • [Cites] Gen Diagn Pathol. 1997 Nov;143(2-3):103-8 [9443567.001]
  • [Cites] Int J Gynecol Pathol. 1994 Jul;13(3):191-8 [7523321.001]
  • [Cites] Int J Gynaecol Obstet. 1995 Jul;49 Suppl:S77-89 [7589744.001]
  • [Cites] Gen Diagn Pathol. 1997 Nov;143(2-3):127-41 [9443570.001]
  • [Cites] Pathol Res Pract. 1997;193(3):225-30; discussion 231-4 [9198108.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1994 Sep;54(9):519-23 [7988856.001]
  • [Cites] J Epidemiol Biostat. 2001;6(1):177-84 [11385775.001]
  • [Cites] Hum Pathol. 1989 Apr;20(4):370-81 [2539322.001]
  • [Cites] Cancer. 1976 Sep;38(3):1214-26 [182351.001]
  • [Cites] Gen Diagn Pathol. 1997 Nov;143(2-3):87-101 [9443566.001]
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1393-403 [9808132.001]
  • [Cites] Pathologe. 1999 Jan;20(1):72-81 [10091235.001]
  • [Cites] J Clin Pathol. 1988 Oct;41(10):1085-8 [3192730.001]
  • [Cites] Int J Gynecol Pathol. 2001 Jan;20(1):31-47 [11192071.001]
  • [Cites] Gen Diagn Pathol. 1997 Nov;143(2-3):143-58 [9443571.001]
  • [Cites] Obstet Gynecol. 1987 Apr;69(4):622-6 [3029643.001]
  • (PMID = 15184992.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Suzuki N, Aoki D, Orikawa K, Suzuki A, Susumu N, Tamada Y, Sakayori M, Tsukazaki K, Mukai M, Kikuchi H, Ishida I, Nozawa S: 8-1A, a human monoclonal antibody that reacts with intact human chorionic gonadotropin. Placenta; 2006 Feb-Mar;27(2-3):333-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of choriocarcinoma has decreased over time and therapeutic results have improved about 90% complete remission in patients without extensive metastasis.
  • However, some choriocarcinomas metastasize to other organs and show resistance to chemotherapy, having a poor prognosis despite multidisciplinary treatment.
  • Better methods of early diagnosis for recurrence or micrometastasis, and treatment against cases with intractable gestational trophoblastic neoplasia (GTN) are needed to improve the prognosis.
  • Human chorionic gonadotropin (hCG) is a glycoprotein hormone composed of two dissimilar subunits and a tumor marker to make a diagnosis and monitor therapeutic effect in GTN.
  • Residual trophoblast cells may cause symptoms such as bleeding or undergo malignant transformation to choriocarcinoma.
  • Since most monoclonal antibodies developed so far are murine, administration creates human anti-mouse antibodies, resulting in clinical failure.
  • In the future, new diagnostic techniques and treatments for chorionic diseases may be developed using this kind of human monoclonal antibody.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16338478.001).
  • [ISSN] 0143-4004
  • [Journal-full-title] Placenta
  • [ISO-abbreviation] Placenta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 8-1A monoclonal antibody, human; 0 / Antibodies, Monoclonal; 0 / Chorionic Gonadotropin
  •  go-up   go-down


24. Williams JB, Mallorga PJ, Conn PJ, Pettibone DJ, Sur C: Effects of typical and atypical antipsychotics on human glycine transporters. Schizophr Res; 2004 Nov 1;71(1):103-12
Hazardous Substances Data Bank. CLOZAPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Augmentation strategy in the treatment of schizophrenia with the NMDA receptor co-agonist glycine has demonstrated significant improvement in patient symptoms.
  • Interestingly, the therapeutic efficacy of glycine was more consistent among patients that were not co-administered clozapine suggesting that clozapine modulates glycine levels in brain.
  • Since cerebral glycine concentration in the vicinity of NMDA receptors is thought to be controlled by the glia expressed glycine transporter type 1 (GlyT1), the effects of several typical and atypical antipsychotics on glycine uptake were examined in human placenta choriocarcinoma (JAR) cells expressing human GlyT1a.
  • The selectivity of these compounds was investigated by measuring their inhibitory potency at the closely related glycine transporter type 2 (GlyT2).
  • Detailed kinetic analysis of hGlyT1a in the presence and absence of haloperidol and clozapine revealed that both drugs were not competitive inhibitors of glycine uptake.
  • Our results have revealed the existence of an inhibitory interaction between some antipsychotics and hGlyT1a and raise the possibility that these drugs could interact with GlyT1 function at therapeutic doses.
  • [MeSH-minor] Animals. Brain / drug effects. Brain / metabolism. Chloride Channels / metabolism. Choriocarcinoma / metabolism. Choriocarcinoma / pathology. Female. Glycine / metabolism. Glycine / pharmacology. Glycine Plasma Membrane Transport Proteins. Humans. Membrane Glycoproteins / antagonists & inhibitors. Membrane Transport Modulators. Membrane Transport Proteins. Rats. Receptors, N-Methyl-D-Aspartate / metabolism. Schizophrenia / drug therapy. Sodium Channels / metabolism. Synapses / metabolism. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RISPERIDONE .
  • Hazardous Substances Data Bank. Olanzapine .
  • Hazardous Substances Data Bank. HALOPERIDOL .
  • Hazardous Substances Data Bank. GLYCINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15374578.001).
  • [ISSN] 0920-9964
  • [Journal-full-title] Schizophrenia research
  • [ISO-abbreviation] Schizophr. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amino Acid Transport Systems, Neutral; 0 / Antipsychotic Agents; 0 / Chloride Channels; 0 / Glycine Plasma Membrane Transport Proteins; 0 / Membrane Glycoproteins; 0 / Membrane Transport Modulators; 0 / Membrane Transport Proteins; 0 / Receptors, N-Methyl-D-Aspartate; 0 / SLC6A5 protein, human; 0 / SLC6A9 protein, human; 0 / Slc6a5 protein, rat; 0 / Slc6a9 protein, rat; 0 / Sodium Channels; 12794-10-4 / Benzodiazepines; 132539-06-1 / olanzapine; 148686-53-7 / taurine transporter; J60AR2IKIC / Clozapine; J6292F8L3D / Haloperidol; L6UH7ZF8HC / Risperidone; TE7660XO1C / Glycine
  •  go-up   go-down


25. Noal S, Joly F, Leblanc E: [Management of gestational trophoblastic disease]. Gynecol Obstet Fertil; 2010 Mar;38(3):193-8
Genetic Alliance. consumer health - Gestational Trophoblastic Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gestational trophoblastic diseases comprise of hydatiform mole, invasive mole, choriocarcinoma and placental site trophoblastic tumor.
  • Placental site trophoblastic tumors are particular chemoresistant pathologies, not secreting hCG which needs specific management.
  • Chemorefractarory patients keep deep prognosis with 5 years survival rate of 43%, which allow development of new therapy in this indication.
  • [MeSH-major] Gestational Trophoblastic Disease / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choriocarcinoma / diagnosis. Choriocarcinoma / epidemiology. Choriocarcinoma / therapy. Chorionic Gonadotropin / blood. Drug Resistance, Neoplasm. Female. Humans. Hydatidiform Mole / diagnosis. Hydatidiform Mole / epidemiology. Hydatidiform Mole / therapy. Pregnancy. Prognosis. Risk Factors. Suction. Trophoblastic Tumor, Placental Site / diagnosis. Trophoblastic Tumor, Placental Site / epidemiology. Trophoblastic Tumor, Placental Site / therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / epidemiology. Uterine Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20189434.001).
  • [ISSN] 1769-6682
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin
  • [Number-of-references] 42
  •  go-up   go-down






Advertisement